http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-047514-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 |
| filingDate | 2005-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34af450328dd7d686e4081d0dab88740 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1e9078a30d1e5c0ccf05ea611776a71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73d0815be70ad289067b52570037f574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_557c1bd57e852d17f42a1700ce32e084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d54055ed35e81af396496644693ab7f |
| publicationDate | 2006-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-047514-A1 |
| titleOfInvention | UREA DERIVATIVES |
| abstract | Compounds of the formula (1) wherein XYDE means CH = CH-CH = CH, N = CH-CH = CH, CH = N-CH = CH, CH = CH-N = CH, CH = CH-CH = N , N = CH-N = CH, CH = N-CH = N, N + (- O -) = CH-CH = CH, CH = N + (- O -) - CH = CH, CH = CH-N + (- O -) = CH, CH = CH-CH = N + (- O-), NH-CO-CH = CH, CH = CH-CO-NH, CO-NH-CH = CH, CH = CH-NH-CO , wherein the H atoms of the -CH- groups may be substituted with Hal, A, OH, OA, A-COO-, Ph- (CH2) n-COO-, cycloalkyl- (CH2) n-COO-, A-CONH, A-CONA-, Ph-CONA, N3, NH2, NO2, CN, COOH, COOA, CONH2, CONHA, WITH (A) 2, O-allyl, O-propargyl and / or O-benzyl; Ph means unsubstituted or mono, di or trisubstituted phenyl with A, OA, OH or Hal; R1 means Hal, C ::: C-H, -C ::: C-A, OH or OA; R2 means H, Hal or A; R3 means 2-oxo-1H-pyridin-1-yl, 2-oxo-1H-pyrazin-1-yl, 2-oxo-piperidin-1-yl, 2-oxo-pyrrolidin-1-yl, 2-oxo- [1,3] oxazinan-3-yl, 3-oxo-morpholin-4-yl, 2-oxo-tetrahydro-pyrimidin-1-yl, 3-oxo-2H-pyridazin-2-yl, 4-oxo-1H -pyridin-1-yl, 2-oxo-imidazolidin-1-yl, 2,6-dioxo-piperidin-1-yl, 2-oxo-piperazin-1-yl, 2,6-dioxo-piperazin-1-yl , 2,5-dioxo-pyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 2-caprolactam-1-yl (= 2-oxo-azepan-1-yl), 2-azabicyclo [2.2.2] -octan-3-on-2-yl, 5,6-dihydro-1H-pyrimidin-2-oxo-1-yl, 4H- [1,4] oxazin-4-yl, 2-imino -piperidin-1-yl, 2-imino-pyrrolidin-1-yl, 3-imino-morpholin-4-yl, 2-imino-imidazolidin-1-yl or unsubstituted 2-imino-1H-pyrazin-1-yl or mono or disubstituted with A, OH and / or OA; A means unbranched, branched or cyclic alkyl with 1-10 C atoms, where 1-7 H atoms can also be replaced by F and / or Cl; Hal means F, Cl, Br or I; n means 0, 1, 2, or 3; as well as its derivatives, solvates, salts and stereoisomers of pharmaceutical utility, including their mixtures in all proportions, compounds that are inhibitors of coagulation factor Xa and can be used for the prevention and / or therapy of thromboembolic diseases and for the treatment of tumors Procedure for preparing compounds of the formula (1). As well as its derivatives, solvates, salts and stereoisomers of pharmaceutical utility. Medications comprising at least one compound of the formula (1). Kit consisting of separate packages of (a) an effective amount of a compound of the formula (1) and / or its derivatives, solvates and stereoisomers of pharmaceutical utility, including mixtures in all proportions, and (b) an effective amount of another active drug ingredient. Intermediate compounds of the formula (2) wherein XYDE means CH = CH-CH = CH, N = CH-CH = CH, CH = N-CH = CH, CH = CH-N = CH, CH = CH-CH = N, N = CH-N = CH, CH = N-CH = N, NH-CO-CH = CH, CH = CH-CO-NH, CO-NH-CH = CH, CH = CH-NH-CO, wherein the H atoms of the -CH- groups may be substituted with Hal, A, OH, OA, A-COO-, Ph- (CH2) n-COO-, cycloalkyl- (CH2) n-COO-, A -CONH, A-CONA-, Ph-CONA, N3, NH2, NO2, CN, COOH, COOA, CONH2, CONHA, WITH (A) 2, O-allyl, O-propargyl and / or O-benzyl; Ph means unsubstituted or mono, di or trisubstituted phenyl with A, OA, OH or Hal; R1 means Hal, C ::: C-H, -C ::: C-A, OH or OA; A means unbranched, branched or cyclic alkyl with 1-10 C atoms, where 1-7 H atoms can be replaced by F and / or Cl; Hal means F, Cl, Br or I; n means 0, 1, 2 or 3; as well as its salts. |
| priorityDate | 2004-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.